Skip to main content
SpringerLink
Log in

Gefitinib affords QOL benefits for NSCLC patients in free access programme

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gefitinib affords QOL benefits for NSCLC patients in free access programme. Pharmacoecon. Outcomes News 420, 10 (2003). https://doi.org/10.1007/BF03276503

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03276503

Keywords

Search

Navigation